PIRS (Pieris Pharmaceuticals Inc) Net Profit

Corporate emblem and logo of pieris.com (PIRS)

Radical headcount reductions and the suspension of tests have locked Pieris Pharmaceuticals (PIRS) into a defensive plateau. The operating model relies on the full outsourcing of molecule development to third-party partners. Research dynamics are independent of economics, following only scientific data. The company's current net result demonstrates a search for reversal points, while the indicator remains at -0.06.

PIRS (Pieris Pharmaceuticals, Inc.) Company Net Income history from 07/04/2022 to 10/30/2026

Financial and market metric breakdowns for Pieris Pharmaceuticals, Inc. (PIRS)

- price and consensus price forecast:
Stock Quotes Pieris Pharma|PIRS - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Pieris Pharma|PIRS - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Pieris Pharmaceuticals|PIRS - Company Book Value|Market-to-Book Ratio pieris.com|PIRS - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Pieris Pharmaceuticals|PIRS - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Pieris Pharmaceuticals Inc|PIRS - Company Aggregate Debts|Debts to Book Value Pieris Pharma|PIRS - Company Long-Term Debt|Company Short-Term Loans and Borrowings Pieris Pharmaceuticals|Critical Liquidity Ratio pieris.com
- net income and valuation multiples indicators:
PIRS - Net Profit
Fundamental valuation:PIRS Pieris Pharma
Flagship merchandise of Pieris Pharmaceuticals Inc

The flexible outsourcing model of Pieris Pharmaceuticals (PIRS) minimizes capital expenditures, making the company's net income a key indicator of operational expense management efficiency. This metric reflects the daily price action of the issuer's real earnings, allowing investors to differentiate the fundamental stability of assets from speculative price volatility and determine the risk of overpaying for the asset during local market peaks.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Company Net Income Theravance Biopharma, Inc. TBPH|AQST (Aquestive Therapeutics Inc) - Profit After Tax|scPharma - Net Profit|Net Financial Result Tectonic Therapeutic, Inc. TECX|TNXP: Net Profit|Company Net Income China SXT Pharmaceuticals, Inc. (SXTC)|Company Net Income Eupraxia Pharmaceuticals, Inc.|BHST: Final Profit|Net Profit EXOZ|Net Financial Result oramed.com|Company Net Income Entera Bio ENTX|Net Financial Result ipatherapeutics.com (HYFT)|ABVC: Net Income|Final Profit CPIX (Cumberland Pharmaceuticals Inc)|Quantum BioPharma Limited (QNTM) - Company Net Income|Profit After Tax FGEN (FibroGen Corporation)|TELO (Telomir Pharmaceuticals) - Net Profit|RANI: Final Profit|Net Profit SNYR|Net Profit rallybio.com (RLYB)|Company Net Income Lexaria Bioscience Corp. LEXX|Final Profit PULM|PTHL - Company Net Income|Aptorum Group Limited (APM) - Net Income|LYRA: Net Profit|impactbiomedinc.com (IBO) - Net Profit|TNFA (TNF Pharmaceuticals Inc.) - Net Profit|Net Income cbdMD Corp (YCBD)|Net Profit PRFX|CYTO - Company Net Income|Lipella Pharmaceuticals, Inc. - Net Income|Net Profit OptiNose Inc OPTN|PROC: Net Income|Petros Pharma - Profit After Payment of Taxes|QLI: Net Profit|SLRN - Net Financial Result|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit